gemcitabine + cisplatin (Memorial Sloan Kettering Cancer Center)

This refers to an investigational treatment regimen developed at Memorial Sloan Kettering Cancer Center (MSKCC) involving the intraperitoneal (IP) administration of gemcitabine in combination with IP cisplatin. Gemcitabine is a pyrimidine nucleoside analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase and competing with deoxycytidine triphosphate for incorporation into DNA. Cisplatin is a platinum-based chemotherapeutic agent that forms covalent bonds with DNA bases, resulting in intra-strand and inter-strand cross-links that inhibit DNA replication and transcription. The regimen was specifically studied in Phase I/II trials for patients with refractory or recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who had persistent disease after standard platinum-based therapy. The protocol was designed to deliver high local concentrations of chemotherapy directly into the peritoneal cavity while minimizing systemic toxicity.

Other names

intraperitoneal gemcitabine and cisplatinIP gemcitabine + IP cisplatingemcitabine-Memorial Sloan Kettering Cancer Center-ovarian cancer-fallopian tube cancer-primary peritoneal cavity cancer